Please Wait.....
Report
Cancer Pain Market Report and Forecast 2024-2032
Market Report (7 Days) I 2024-04-16 I 140 Pages I EMR Inc.
Cancer Pain Market Report and Forecast 2024-2032
Cancer Pain Market Overview
The cancer pain market size was valued at USD 6.53 billion in 2023, driven by increasing cancer incidence and rising demand for effective therapeutics to manage cancer pain across the 8 major markets. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2024-2032, with the values likely to rise from USD 6.9 billion in 2024 to USD 10.66 billion by 2032.
Cancer pain is a complex and multidimensional symptom that affects the quality of life of cancer patients. Cancer pain can be caused by the tumor itself, the treatments, or the side effects of the treatments. Cancer pain can be acute or chronic, and can vary in intensity, frequency, and duration. The management of cancer pain involves a multidisciplinary approach that includes pharmacological and non-pharmacological interventions, such as opioids, non-opioids, adjuvants, nerve blocks, radiotherapy, surgery, psychological therapies, and complementary therapies.
Cancer Pain Market Drivers and Constraints
The key drivers of the global cancer pain market are:
- The increasing prevalence and incidence of cancer worldwide, especially in the aging population.
- The rising awareness and demand for effective pain management among cancer patients and caregivers.
- The development and launch of novel and innovative products, such as extended-release formulations, transdermal patches, and abuse-deterrent formulations, that offer better efficacy, safety, and convenience.
- The expansion of the indications and the patient population for existing products, such as opioids, adjuvants, and cannabinoids.
- The favorable reimbursement policies and government initiatives that support the access and affordability of cancer pain treatments.
The key constraints of the global cancer pain market are:
- The high cost and low availability of some of the cancer pain treatments, especially in the developing and underdeveloped regions.
- The stringent regulatory requirements and the long approval process for new products and indications.
- The lack of standardized guidelines and protocols for cancer pain assessment and management across different regions and settings.
- The low awareness and education among healthcare professionals and patients about the optimal use of cancer pain treatments.
- The social stigma and legal barriers associated with some of the cancer pain treatments, such as opioids and cannabinoids.
Cancer Pain Market Trends and Developments
- Increasing Incidence of Cancer: The rising global incidence of cancer is leading to a greater number of patients requiring pain management, thereby driving the demand for cancer pain treatments.
- Advancements in Pain Management Therapies: There is ongoing research and development of new analgesics, including non-opioid medications, targeted therapies, and combination treatments, to provide more effective and safer options for cancer pain management.
- Shift Towards Personalized Medicine: Personalized pain management approaches, based on the genetic makeup of patients and the specific characteristics of their cancer, are being explored to optimize treatment outcomes.
- Integration of Multimodal Approaches: The trend towards multimodal pain management, which combines pharmacological and non-pharmacological therapies (such as physical therapy, acupuncture, and psychological support), is gaining traction for a more holistic approach to cancer pain.
- Focus on Quality of Life: There is an increasing emphasis on assessing and improving the quality of life for cancer patients, with pain management being a crucial aspect of palliative care.
- Use of Advanced Drug Delivery Systems: Innovations in drug delivery systems, such as transdermal patches, implantable pumps, and extended-release formulations, are improving the efficacy and convenience of cancer pain treatments.
- Growing Awareness and Education: Efforts to raise awareness among healthcare professionals and patients about effective cancer pain management strategies are contributing to better pain control and treatment adherence.
- Regulatory Challenges and Opioid Concerns: The opioid crisis has led to stricter regulations and guidelines for prescribing opioid analgesics, impacting the cancer pain market and necessitating the development of alternative pain management options.
Cancer Pain Market Segmentation
Market Breakup by Drug Type?
- Opioids
o Fentanyl
o Morphine
o Others
- Non-Opioids?
o Acetaminophen
o Non-Steroidal Anti-Inflammatory Drug
- Nerve Blockers
Market Breakup by Indication?Type
- Lung Cancer?
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
- Others?
Market Breakup by Treatment Type
- Immunotherapy??
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
- India
Cancer Pain Market: Competitive Landscape
The market report encompasses comprehensive analyses, including patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, as well as partnerships and collaborations analysis conducted by the leading key players in the market. Among the major companies contributing to this market are Eli Lilly, HISAMITSU PHARMACEUTICAL CO., INC., Aoxing Pharmaceutical Company, Inc., GRUNENTHAL PHARMA GmbH & CO. KG, PFIZER INC., BIODELIVERY SCIENCES INTERNATIONAL, INC., OREXO AB, Johnson and Johnson, Medtronic plc, Novartis AG, and Glaxo SmithKline Plc. These analyses and the involvement of these prominent players highlight the dynamic and evolving nature of the market, underlining the significant investments and collaborations driving advancements and growth in the field.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Pain Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Pain Epidemiology Analysis - 8MM
5.1 8MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Cancer Pain Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
5.3.1 Germany Cancer Pain Epidemiology Forecast (2017-2032)
5.3.2 France Cancer Pain Epidemiology Forecast (2017-2032)
5.3.3 Italy Cancer Pain Epidemiology Forecast (2017-2032)
5.3.4 Spain Cancer Pain Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
5.4 Japan Cancer Pain Epidemiology Forecast (2017-2032)
5.5 India Cancer Pain Epidemiology Forecast (2017-2032)
6 Cancer Pain Market Overview - 8MM
6.1 Cancer Pain Market Historical Value (2017-2023)
6.2 Cancer Pain Market Forecast Value (2024-2032)
7 Cancer Pain Market Landscape - 8MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cancer Pain Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Indication Type
7.2.3 Analysis by Treatment Type
8 Cancer Pain Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cancer Pain Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cancer Pain Market Segmentation - 8MM
11.1 Cancer Pain Market by Drug Type
11.1.1 Market Overview
11.1.2 Opioids
11.1.2.1 Fentanyl
11.1.2.2 Morphine
11.1.2.3 Others
11.1.3 Non-Opioids
11.1.3.1 Acetaminophen
11.1.3.2 Non-Steroidal Anti-Inflammatory Drugs
11.1.4 Nerve Blockers
11.2 Cancer Pain Market by Indication Type
11.2.1 Market Overview
11.2.2 Lung Cancer
11.2.3 Colorectal Cancer
11.2.4 Breast Cancer
11.2.5 Prostate Cancer
11.2.6 Blood Cancer
11.2.7 Others
11.3 Cancer Pain Market by Treatment Type
11.3.1 Market Overview
11.3.2 Immunotherapy
11.3.3 Chemotherapy
11.3.4 Targeted Therapy
11.3.5 Hormonal Therapy
11.4 Cancer Pain Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Cancer Pain Market
12.1 Cancer Pain Market Historical Value (2017-2023)
12.2 Cancer Pain Market Forecast Value (2024-2032)
12.3 Cancer Pain Market by Drug Type
12.4 Cancer Pain Market by Indication Type
13 EU-4 and United Kingdom Cancer Pain Market
13.1 Cancer Pain Market Historical Value (2017-2023)
13.2 Cancer Pain Market Forecast Value (2024-2032)
13.3 Germany Cancer Pain Market Overview
13.3.1 Cancer Pain Market by Drug Type
13.3.2 Cancer Pain Market by Indication Type
13.4 France Cancer Pain Market Overview
13.4.1 Cancer Pain Market by Drug Type
13.4.2 Cancer Pain Market by Indication Type
13.5 Italy Cancer Pain Market Overview
13.5.1 Cancer Pain Market by Drug Type
13.5.2 Cancer Pain Market by Indication Type
13.6 Spain Cancer Pain Market Overview
13.6.1 Cancer Pain Market by Drug Type
13.6.2 Cancer Pain Market by Indication Type
13.7 United Kingdom Cancer Pain Market Overview
13.7.1 Cancer Pain Market by Drug Type
13.7.2 Cancer Pain Market by Indication Type
14 Japan Cancer Pain Market
14.1 Cancer Pain Market Historical Value (2017-2023)
14.2 Cancer Pain Market Forecast Value (2024-2032)
14.3 Cancer Pain Market by Drug Type
14.4 Cancer Pain Market by Indication Type
15 India Cancer Pain Market
15.1 Cancer Pain Market Historical Value (2017-2023)
15.2 Cancer Pain Market Forecast Value (2024-2032)
15.3 Cancer Pain Market by Drug Type
15.4 Cancer Pain Market by Indication Type
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 India CDSCO
16.1.4 JAPAN PMDA
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnerships and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Eli Lilly
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 HISAMITSU PHARMACEUTICAL CO., INC.,
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Aoxing pharmaceutical company, inc.,
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 GRUNENTHAL PHARMA GmbH & CO. KG
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 PFIZER INC.,
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 BIODELIVERY SCIENCES INTERNATIONAL, INC.,
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 OREXO AB
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Johnson and Johnson
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Medtronic plc
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Novartis AG
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Glaxo SmithKline Plc
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
23 Cancer Pain Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security